This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Osteoporosis	CD40 ligand (CD40LG; CD40L; CD154)	<p>Mouse studies suggest that inhibiting CD40L could help treat postmenopausal osteoporosis. In a mouse model of postmenopausal osteoporosis, Cd40l knockout or an anti-CD40L antibody decreased bone loss compared with that in wild-type or inactive antibody-treated controls. Future studies could include testing CD40L inhibition in other models of osteoporosis.</p> <p>CDP7657 (Anti-CD40L Fab), a Fab antibody targeting CD40L from Biogen Idec Inc. and UCB Group, is in Phase I testing to treat systemic lupus erythematosus (SLE).</p> <p>SciBX 4(4); doi:10.1038/scibx.2011.111 Published online Jan. 27, 2011</p>	Patent and licensing status unavailable	<p>Li, J.-Y. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 27, 2010; doi:10.1073/pnas.1013492108</p> <p>Contact: Roberto Pacifici, Emory University, Atlanta, Ga. e-mail: roberto.pacifici@emory.edu</p>